BioXtek Company Profile

Background

Overview

BioXtek is a biotechnology company specializing in regenerative therapeutics derived from human placental tissues. Established in 2022 and headquartered in Pompano Beach, Florida, BioXtek focuses on developing pharmaceutical-grade therapies aimed at regenerating damaged or diseased tissues at the cellular level. The company's mission is to introduce a new biologic paradigm to allopathic medical treatments, enhancing patient outcomes across a wide spectrum of medical and surgical conditions without side effects or adverse events.

Mission and Vision

BioXtek envisions medical therapeutics derived from human placental tissues and their components to be processed into pharmaceutical-grade therapies to regenerate sick or injured tissues at the cellular level. The company's mission is to bring a new biologic paradigm to allopathic medical treatments for improved patient outcomes in a wide spectrum of medical and surgical pathologies, without side effects or adverse events, and high levels of patient successful outcomes.

Industry Significance

BioXtek operates within the regenerative medicine sector, focusing on placental-derived biologics. This field is significant due to its potential to address unmet medical needs by promoting tissue regeneration and healing, thereby improving patient quality of life and reducing healthcare costs associated with chronic conditions and injuries.

Key Strategic Focus

Core Objectives

BioXtek aims to develop and commercialize regenerative therapeutics that utilize human placental tissues to promote tissue regeneration and healing. The company focuses on creating products that are free from side effects and adverse events, ensuring high levels of patient success across various medical and surgical conditions.

Areas of Specialization

The company specializes in regenerative medicine, particularly in the development of therapies derived from human placental tissues, including amniotic fluid and Wharton’s jelly. These components are rich in growth factors, cytokines, exosomes, and other bioactive molecules essential for tissue regeneration and healing.

Key Technologies Utilized

BioXtek employs advanced biotechnological techniques, including cryopreservation and freeze-drying, to concentrate and preserve biologically active components such as exosomes, growth factors, peptides, cytokines, miRNA, and mesenchymal stem cells. The company utilizes the BioPür Process®, a proprietary platform technology designed to preserve the bioactive properties of placental tissues during processing.

Primary Markets Targeted

BioXtek targets markets in wound care, orthopedics, and regenerative organ therapeutics. The company's products are designed to address conditions such as chronic wounds, tendon and nerve injuries, and various organ pathologies, including cardiac and pulmonary conditions.

Financials and Funding

Funding History

BioXtek has raised a total of $2 million in seed funding.

Recent Funding Rounds

The company has completed a seed funding round, securing $2 million to support its research and development efforts.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Utilization of Capital

The raised capital is intended to support BioXtek's research and development initiatives, including the advancement of its regenerative therapeutics pipeline, expansion of manufacturing capabilities, and regulatory compliance efforts.

Pipeline Development

Key Pipeline Candidates

BioXtek's pipeline includes:

Membrane Patches: Derived from human placental sac, available in various configurations (single-layer, dual-layer, tri-layer, and quad-layer) for applications such as wound care, tendon and nerve repair, and cardiac surgeries.

Injectable Regenerative Therapeutics (BioXsomes): Designed for a wide range of medical uses, including wound care, burn treatments, heart, lung, and kidney therapies. The company is pursuing a biologic license from the US FDA for this product.

Topical Cosmetics: Utilizing placental-derived exosomes and bioactive molecules to enhance skin regeneration and rejuvenation.

Stages of Development

The membrane patches and topical cosmetics are in advanced stages of development, with ongoing clinical evaluations. The injectable regenerative therapeutics are in the preclinical stage, with plans to submit a biologic license application to the FDA.

Target Conditions

The pipeline targets conditions such as chronic wounds, tendon and nerve injuries, burns, cardiac and pulmonary diseases, and dermatological concerns addressed by cosmetic applications.

Anticipated Milestones

Key milestones include:

Membrane Patches: Completion of clinical trials and market introduction.

Injectable Regenerative Therapeutics: FDA biologic license application submission and subsequent approval.

Topical Cosmetics: Product launch following successful clinical outcomes.

Technological Platform and Innovation

Proprietary Technologies

BioXtek's proprietary BioPür Process® ensures the preservation of bioactive properties in placental tissues during processing, maintaining the integrity of exosomes, growth factors, and other essential molecules.

Significant Scientific Methods

The company employs advanced cryopreservation and freeze-drying techniques to concentrate and stabilize biologically active components, facilitating their use in regenerative therapies.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, BioXtek utilizes advanced biotechnological processes to enhance the efficacy and safety of its products.

Leadership Team

Key Executives

Dr. Bruce Werber, DPM, MSc, FACFAS: CEO & Founder. A seasoned entrepreneur, physician, and researcher with over 15 years in regenerative medicine.

Terrell Suddarth: COO & Founder. Experienced in quality and operations management within the defense contractor, medical device, and biotechnology sectors.

Carmen Kerschbaum: CFO. An entrepreneurial business leader with a strong passion for driving results through process implementation and leading multicultural teams.

Leadership Changes

As of February 7, 2025, Dr. Peter A. M. Everts was appointed as the Chief Scientific and Technology Officer, enhancing BioXtek's scientific capabilities.

Competitor Profile

Market Insights and Dynamics

The regenerative medicine market, particularly focusing on placental-derived therapeutics, is experiencing significant growth due to increasing demand for advanced healing solutions and the potential to address unmet medical needs.

Competitor Analysis

Key competitors in the regenerative medicine sector include companies specializing in stem cell therapies, tissue engineering, and biologic products derived from human tissues. Specific competitor names and details are not provided in the available information.

Strategic Collaborations and Partnerships

In February 2025, BioXtek formed a joint venture with Zeo ScientifiX to develop, manufacture, market, and fund biologic regenerative therapeutics. This collaboration aims to enhance operational efficiencies and secure FDA approval for new products.

Operational Insights

BioXtek's compliance with full cGMP and cGTP standards, supported by a robust quality system, positions the company favorably in the competitive landscape.

Strategic Opportunities and Future Directions

BioXtek's strategic roadmap includes expanding its product portfolio, advancing clinical trials, and obtaining regulatory approvals to address a broader range of medical conditions. The company's focus on innovation and quality positions it to achieve future objectives in the regenerative medicine market.